The safety review committee (SRC) has reviewed the data from the fourth cohort of Skye Bioscience’s Phase I clinical trial of SBI-100 Ophthalmic Emulsion (OE) and has given approval to proceed with the fifth cohort.

Patients of the first, second, and third cohorts who received SBI-100 in the Phase I trial reported no adverse events.

Mild to moderate drug-related adverse events, which are typically associated with topical eye treatments, were reported across all cohorts.

A total of 24 subjects were enrolled in the three cohorts. Out of the total, 18 subjects received a single dose of 0.5%, 1%, and 2% SBI-100 OE in their respective single ascending dose (SAD) arm studies, and the remaining received a placebo.

In the first cohort’s multiple ascending dose (MAD) arm study, six healthy subjects were treated with a single dose of 0.5% SBI-100 OE in the morning and evening for five days while the remaining received a placebo.

For a total of seven days, including the five days of dosing, subjects were monitored at the clinical research unit in Adelaide, Australia.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Fifth and sixth cohort subjects are expected to receive 1% and 2% SBI-100 OE this month and later next month, respectively.

SBI-100 OE is formulated as an eye drop using a propriety nanoemulsion. It targets the CB1 receptor, which plays an important role in managing intraocular pressure associated with glaucoma, a leading cause of irreversible blindness.

Results were found to be favourable in preclinical studies of SBI-100 OE as a single agent and along with standard of care (SOC) glaucoma drugs, compared to SOC alone and other combinations.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now